Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A
Background: Lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, is approved for advanced (unresectable or metastatic) melanoma previously treated with a PD-1-blocking antibody, and, if BRAF V600 mutation–positive, a BRAF inhibitor with or without a MEK inhibitor. Cohort 1A of the IOV-COM-202 study (NCT03645928) assesses the efficacy and safety of lifileucel and pembrolizumab in an earlier setting for patients with immune checkpoint inhibitor (ICI)–naive advanced melanoma.
Authors
- Simon Haefliger (ORCID: https://orcid.org/0000-0002-9721-3314)
- Gino K. In (ORCID: https://orcid.org/0000-0002-7060-5123)
- Patrick Terheyden (ORCID: https://orcid.org/0000-0002-5894-1677)
- M. Catlett
- Rana Fiaz
- Jeffrey Chou (ORCID: https://orcid.org/0000-0001-9232-0092)
- S. Thomas
- G. Chen
- Bernard Doger de Spéville Uribe
- Donald P. Lawrence (ORCID: https://orcid.org/0000-0001-5288-9110)
- Andrew J.S. Furness (ORCID: https://orcid.org/0000-0002-2358-9730)
- S. Lee
- Juan Martín-Liberal (ORCID: https://orcid.org/0000-0003-2552-5172)
- K. He
- Y.K. Hong
- Brian Gastman (ORCID: https://orcid.org/0000-0003-2691-3409)
- Helen J Gogas (ORCID: https://orcid.org/0000-0002-0451-2885)
- Friedrich Graf Finckenstein (ORCID: https://orcid.org/0009-0009-6251-6903)
- A. García Castaño
- Theresa M. Medina (ORCID: https://orcid.org/0009-0002-3799-4320)
Institutions
- University of Southern California (US)
- Royal Marsden NHS Foundation Trust (GB)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Orlando Health (US)
- National and Kapodistrian University of Athens (GR)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Cooper University Hospital (US)
- University Hospital of Bern (CH)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Marqués de Valdecilla University Hospital (ES)
- Laiko General Hospital of Athens (GR)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Theravance Biopharma (United States) (US)
- University of Colorado Cancer Center (US)
- Duran i Reynals Hospital (ES)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
- University of Lübeck (DE)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100624
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14